HotSpot Therapeutics, Inc.

HotSpot Therapeutics is a Boston-based clinical-stage biopharmaceutical company pioneering a new class of allosteric medicines. Using its proprietary Smart Allostery and SpotFinder platforms, the company systematically identifies 'natural hotspots' - regulatory allosteric pockets the body uses to switch proteins on and off - to drug targets long considered undruggable. Its small-molecule pipeline spans oncology (CBL-B, CBM signalosome/KRAS) and autoimmune disease (IRF5), with its lead CBL-B inhibitor HST-1011 in Phase 1/2 clinical trials.